Evidence map›Paper›PMID 38324323›Full record

SynthesisJAMA psychiatry2024

Parameter Space and Potential for Biomarker Development in 25 Years of fMRI Drug Cue Reactivity: A Systematic Review.

Addiction Cue-Reactivity Initiative (ACRI) Network, Arshiya Sangchooli, Mehran Zare-Bidoky, Ali Fathi Jouzdani, Joseph Schacht, James M Bjork, Eric D Claus, James J Prisciandaro, Stephen J Wilson, Torsten Wüstenberg and 59 more

Open access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in JAMA psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. The neural and psychophysiological effects of cannabidiol in youth with alcohol use disorder: A randomized controlled clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
  8. Drawbacks to Strengthening Neural Salience Encoding: A Link Between Cortisol and Risky Drinking.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Trial
  9. Cue-elicited prefrontal gamma-aminobutyric acid (GABA) dynamics in cannabis use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  10. Article
  11. The neurobiological cravings signature (NCS) as a predictive neuromarker of clinical outcomes in alcohol use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Four dimensions of individualization in brain stimulation for psychiatric disorders: context, target, dose, and timing.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

69 authors at 20 institutions in 11 countries.

Addiction Cue-Reactivity Initiative (ACRI) Network
Arshiya SangchooliMelbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia.
Mehran Zare-BidokyDepartment of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis.
Ali Fathi JouzdaniIranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.
Joseph SchachtDepartment of Psychiatry, University of Colorado School of Medicine, Aurora.
James M BjorkInstitute for Drug and Alcohol Studies, Department of Psychiatry, Virginia Commonwealth University, Richmond.
Eric D ClausDepartment of Biobehavioral Health, The Pennsylvania State University, University Park.
James J PrisciandaroAddiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston.
Stephen J WilsonDepartment of Psychology, The Pennsylvania State University, State College.
Torsten WüstenbergField of Focus IV, Core Facility for Neuroscience of Self-Regulation (CNSR), Heidelberg University, Heidelberg, Germany.
Stéphane PotvinDepartment of Psychiatry and Addiction, Université de Montréal, Montréal, Quebec, Canada.
Pooria AhmadiDepartment of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Patrick BachDepartment of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Alex BaldacchinoSchool of Medicine, University of St Andrews, St Andrews, Scotland.
Anne BeckFaculty of Health, Health and Medical University, Potsdam, Germany.
Kathleen T BradyAddiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston.
Judson A BrewerDepartment of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island.
Anna Rose ChildressPerelman School of Medicine, University of Pennsylvania, Philadelphia.
Kelly E CourtneyDepartment of Psychiatry, University of California, San Diego.
Mohsen EbrahimiIranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.
Francesca M FilbeyCenter for BrainHealth, School of Behavioral and Brain Sciences, University of Texas at Dallas.
Hugh GaravanDepartment of Psychiatry, University of Vermont, Burlington.
Dara G GhahremaniDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles.
Rita Z GoldsteinDepartments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York.
Anneke E GoudriaanDepartment of Psychiatry, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Erica N GrodinDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles.
Colleen A HanlonDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Amelie HauggDepartment of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Markus HeiligCenter for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Andreas HeinzDepartment of Psychiatry and Neurosciences, Charité Campus Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Adrienn HolczerDepartment of Neurology, Albert Szent-Györgyi Health Centre, University of Szeged, Szeged, Hungary.
Ruth J Van HolstAmsterdam Institute for Addiction Research, Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Jane E JosephDepartment of Neuroscience, Medical University of South Carolina, Charleston.
Anthony C JulianoDepartment of Psychiatry, University of Vermont, Burlington.
Marc J KaufmanMcLean Hospital, Harvard Medical School, Belmont, Massachusetts.
Falk KieferDepartment of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Arash Khojasteh ZonooziIranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.
Rayus T KuplickiLaureate Institute for Brain Research, Tulsa, Oklahoma.
Marco LeytonDepartment of Psychiatry, McGill University, Montreal, Quebec, Canada.
Edythe D LondonDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles.
Scott MackeyDepartment of Psychiatry, University of Vermont, Burlington.
F Joseph McClernonDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina.
William H MellickAddiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston.
Kirsten MorleySpecialty of Addiction Medicine, Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, Australia.
Hamid R NooriMcGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge.
Mohammad Ali OghabianNeuroimaging and Analysis Group, Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran.
Jason A OliverTSET Health Promotion Research Center, University of Oklahoma Health Sciences Center, Oklahoma City.
Max OwensDepartment of Psychiatry, University of Vermont, Burlington.
Martin P PaulusLaureate Institute for Brain Research, Tulsa, Oklahoma.
Irene PeriniCenter for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Parnian RafeiIranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.
Lara A RayDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles.
Rajita SinhaDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Michael N SmolkaDepartment of Psychiatry, Technische Universität Dresden, Dresden, Germany.
Ghazaleh SoleimaniDepartment of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis.
Rainer SpanagelInstitute of Psychopharmacology, Central Institute of Mental Health, Mannheim, Germany.
Vaughn R SteeleDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Susan F TapertDepartment of Psychiatry, University of California, San Diego.
Sabine Vollstädt-KleinDepartment of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Reagan R WetherillPerelman School of Medicine, University of Pennsylvania, Philadelphia.
Katie WitkiewitzDepartment of Psychology, University of New Mexico, Albuquerque.
Kai YuanSchool of Life Science and Technology, Xidian University, Xi'an, China.
Xiaochu ZhangDepartment of Psychology, School of Humanities and Social Science, University of Science and Technology of China, Anhui, China.
Antonio Verdejo-GarciaTurner Institute for Brain and Mental Health, Monash University, Clayton, Australia.
Marc N PotenzaDepartment of Psychiatry, Technische Universität Dresden, Dresden, Germany.
Amy C JanesCognitive and Pharmacological Neuroimaging Unit, National Institute on Drug Abuse, Baltimore, Maryland.
Hedy KoberDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Anna ZilverstandDepartment of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis.
Hamed EkhtiariDepartment of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis.
University of Vermont · USUniversity of Minnesota · USUniversity of California, Los Angeles · USHeidelberg University · DELinköping University · SEMedical University of South Carolina · USPennsylvania State University · USYale University · USLaureate Institute for Brain Research · USNational Institute on Drug Abuse · USThe University of Sydney · AUUniversity of British Columbia · CAUniversity of California San Diego · USUniversity of Science and Technology of China · CNUniversity of St Andrews · GBUniversity of Szeged · HUAmsterdam Neuroscience · NLBrown University · USHarvard University · USMcGovern Institute for Brain Research · US

Funding

TREATING ETHANOL WITHDRAWAL WITH LORAZEPAM/NALTREXONEP50AA010761 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Lisa M McTeague · 1996 to 2026
$46.8M
TSF to enhance treatment of cocaine dependenceP50DA009241 · NIDA · YALE UNIVERSITY · PI KOBER, HEDY · 1994 to 2018
$40.5M
SUBSTANCE ABUSEK12DA000167 · NIDA · YALE UNIVERSITY · PI STEPHANIE S O'MALLEY, Marc N Potenza · 1991 to 2026
$17.7M
Defining neurobiological links between substance use and mental illnessZIADA000641 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI JANES, AMY · 2022 to 2025
$8.8M
ENIGMA- Addiction: Pooling of Existing Datasets to Identify Brain and Genetic Correlates of Addiction, Next StepsR01DA047119 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HUGH P. GARAVAN · 2018 to 2026
$5.4M
Atherosclerosis in cocaine addiction: imaging risk with PET/MRR01DA049547 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Nelly Alia-Klein, Zahi A. Fayad · 2022 to 2026
$3.9M
Neuroimaging response inhibition and salience attribution changes during mindfulness-based treatment of human heroin addictionR01AT010627 · NCCIH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GOLDSTEIN, RITA Z · 2019 to 2023
$3.8M
Neural Mechanisms of Behavior Change in a Community Sample of DrinkersR01AA023665 · NIAAA · THE MIND RESEARCH NETWORK · PI CLAUS, ERIC D, WITKIEWITZ, KATIE A · 2015 to 2019
$3.6M
Sex differences in the neural correlates underlying impairments in response inhibition and salience attribution in cocaine addictionR01DA048301 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GOLDSTEIN, RITA Z · 2020 to 2024
$3.4M
Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural FunctionR01DA045162 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK, MOONEY, LARISSA JEANETTE · 2018 to 2022
$3.3M
Using event-related potentials to longitudinally track cue-induced craving incubation in cocaine addicted individualsR01DA041528 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GOLDSTEIN, RITA Z · 2016 to 2020
$3.3M
Gabapentin for Restoring GABA/glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Clinical MRI StudyR01DA054275 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PRISCIANDARO, JAMES JOSEPH · 2021 to 2025
$3.1M
NCCIH NIH HHS R01 AT007922NCCIH NIH HHS R01 AT010627NCCIH NIH HHS R34 AT008948NCCIH NIH HHS R61 AT009337NCI NIH HHS R21 CA184254NIAAA NIH HHS K01 AA029712NIAAA NIH HHS K23 AA028535NIAAA NIH HHS K24 AA030788NIAAA NIH HHS P50 AA010761NIAAA NIH HHS R01 AA023665NIAAA NIH HHS R01 AA025365NIAAA NIH HHS R01 AA026859NIAAA NIH HHS R01 AA027765NIAAA NIH HHS R01 AA029406NIAAA NIH HHS R01 AA029611NIAAA NIH HHS R21 AA030284NIA NIH HHS R21 AG062004NIDA NIH HHS K12 DA000167NIDA NIH HHS K23 DA042898NIDA NIH HHS P50 DA009241NIDA NIH HHS R01 DA041528NIDA NIH HHS R01 DA041866NIDA NIH HHS R01 DA042490NIDA NIH HHS R01 DA045162NIDA NIH HHS R01 DA047119NIDA NIH HHS R01 DA047851NIDA NIH HHS R01 DA048301NIDA NIH HHS R01 DA049547NIDA NIH HHS R01 DA053342NIDA NIH HHS R01 DA054275NIDA NIH HHS R01 DA055774NIDA NIH HHS R01 DA057567NIDA NIH HHS R03 DA029163NIDA NIH HHS R03 DA052719NIDA NIH HHS R21 DA045853NIDA NIH HHS R21 DA054281NIDA NIH HHS R34 DA037886NIDA NIH HHS R37 DA044467NIDA NIH HHS UG1 DA050207NIDA NIH HHS UG3 DA048388NIDDK NIH HHS R01 DK121551NIMH NIH HHS R41 MH118130NIMH NIH HHS RF1 MH128614
6 · The paper itself

Abstract

Importance: In the last 25 years, functional magnetic resonance imaging drug cue reactivity (FDCR) studies have characterized some core aspects in the neurobiology of drug addiction. However, no FDCR-derived biomarkers have been approved for treatment development or clinical adoption. Traversing this translational gap requires a systematic assessment of the FDCR literature evidence, its heterogeneity, and an evaluation of possible clinical uses of FDCR-derived biomarkers. Objective: To summarize the state of the field of FDCR, assess their potential for biomarker development, and outline a clear process for biomarker qualification to guide future research and validation efforts. Evidence Review: The PubMed and Medline databases were searched for every original FDCR investigation published from database inception until December 2022. Collected data covered study design, participant characteristics, FDCR task design, and whether each study provided evidence that might potentially help develop susceptibility, diagnostic, response, prognostic, predictive, or severity biomarkers for 1 or more addictive disorders. Findings: There were 415 FDCR studies published between 1998 and 2022. Most focused on nicotine (122 [29.6%]), alcohol (120 [29.2%]), or cocaine (46 [11.1%]), and most used visual cues (354 [85.3%]). Together, these studies recruited 19 311 participants, including 13 812 individuals with past or current substance use disorders. Most studies could potentially support biomarker development, including diagnostic (143 [32.7%]), treatment response (141 [32.3%]), severity (84 [19.2%]), prognostic (30 [6.9%]), predictive (25 [5.7%]), monitoring (12 [2.7%]), and susceptibility (2 [0.5%]) biomarkers. A total of 155 interventional studies used FDCR, mostly to investigate pharmacological (67 [43.2%]) or cognitive/behavioral (51 [32.9%]) interventions; 141 studies used FDCR as a response measure, of which 125 (88.7%) reported significant interventional FDCR alterations; and 25 studies used FDCR as an intervention outcome predictor, with 24 (96%) finding significant associations between FDCR markers and treatment outcomes. Conclusions and Relevance: Based on this systematic review and the proposed biomarker development framework, there is a pathway for the development and regulatory qualification of FDCR-based biomarkers of addiction and recovery. Further validation could support the use of FDCR-derived measures, potentially accelerating treatment development and improving diagnostic, prognostic, and predictive clinical judgments.

Indexed as

BiomarkersCuesMagnetic Resonance ImagingSubstance-Related DisordersBrainFunctional NeuroimagingHumansBiomarkers

Identifiers

PMID38324323
PMCPMC11304510
OpenAlexW4391598248

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.